Cargando…

Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy

BACKGROUND AND PURPOSE: Cannabis has been used to treat epilepsy for millennia, with such use validated by regulatory approval of cannabidiol (CBD) for Dravet syndrome. Unregulated artisanal cannabis‐based products used to treat children with intractable epilepsies often contain relatively low doses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anderson, Lyndsey L., Heblinski, Marika, Absalom, Nathan L., Hawkins, Nicole A., Bowen, Michael T., Benson, Melissa J., Zhang, Fan, Bahceci, Dilara, Doohan, Peter T., Chebib, Mary, McGregor, Iain S., Kearney, Jennifer A., Arnold, Jonathon C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292928/ https://www.ncbi.nlm.nih.gov/pubmed/34384142 http://dx.doi.org/10.1111/bph.15661

Ejemplares similares

Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome
por: Anderson, Lyndsey L., et al.
Publicado: (2022)

Heterozygous deletion of Gpr55 does not affect a hyperthermia-induced seizure, spontaneous seizures or survival in the Scn1a(+/)(-) mouse model of Dravet syndrome
por: Anderson, Lyndsey L., et al.
Publicado: (2023)

Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels
por: Heblinski, Marika, et al.
Publicado: (2020)

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
por: Anderson, Lyndsey L., et al.
Publicado: (2019)

Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile
por: Swift, Wendy, et al.
Publicado: (2013)

Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations
por: Anderson, Lyndsey L., et al.
Publicado: (2021)

The Heat Sensing Trpv1 Receptor Is Not a Viable Anticonvulsant Drug Target in the Scn1a (+/−) Mouse Model of Dravet Syndrome
por: Satpute Janve, Vaishali, et al.
Publicado: (2021)

The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels
por: Udoh, Michael, et al.
Publicado: (2022)

Biosynthesis of cannabigerol and cannabigerolic acid: the gateways to further cannabinoid production
por: Kearsey, Lewis J, et al.
Publicado: (2023)

A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function
por: Milligan, Carol J., et al.
Publicado: (2022)

Prescribing medicinal cannabis
por: Arnold, Jonathon C, et al.
Publicado: (2020)

The Origin and Biomedical Relevance of Cannabigerol
por: Jastrząb, Anna, et al.
Publicado: (2022)

Evaluation of the Possible Anticonvulsant Effect of Δ(9)-Tetrahydrocannabinolic Acid in Murine Seizure Models
por: Benson, Melissa J., et al.
Publicado: (2022)

SNP in Potentially Defunct Tetrahydrocannabinolic Acid Synthase Is a Marker for Cannabigerolic Acid Dominance in Cannabis sativa L.
por: Garfinkel, Andrea R., et al.
Publicado: (2021)

Medical cannabis use in the Australian community following introduction of legal access: the 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18)
por: Lintzeris, Nicholas, et al.
Publicado: (2020)

Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20)
por: Lintzeris, Nicholas, et al.
Publicado: (2022)

Anti-Biofilm Activity of Cannabigerol against Streptococcus mutans
por: Aqawi, Muna, et al.
Publicado: (2021)

Anti-Bacterial Properties of Cannabigerol Toward Streptococcus mutans
por: Aqawi, Muna, et al.
Publicado: (2021)

Acute Cannabigerol Administration Lowers Blood Pressure in Mice
por: Vernail, Victoria L., et al.
Publicado: (2022)

MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy
por: Harman, Thomas, et al.
Publicado: (2023)

Oxylipin biosynthetic gene families of Cannabis sativa
por: Borrego, Eli J., et al.
Publicado: (2023)

Cannabigerol Prevents Quorum Sensing and Biofilm Formation of Vibrio harveyi
por: Aqawi, Muna, et al.
Publicado: (2020)

Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives
por: Calapai, Fabrizio, et al.
Publicado: (2022)

Chronic Cannabigerol as an Effective Therapeutic for Cisplatin-Induced Neuropathic Pain
por: Nachnani, Rahul, et al.
Publicado: (2023)

Characteristics of the Diploid, Triploid, and Tetraploid Versions of a Cannabigerol-Dominant F(1) Hybrid Industrial Hemp Cultivar, Cannabis sativa ‘Stem Cell CBG’
por: Crawford, Seth, et al.
Publicado: (2021)

In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid
por: Gugliandolo, Agnese, et al.
Publicado: (2018)

Chemotherapy‐induced cachexia dysregulates hypothalamic and systemic lipoamines and is attenuated by cannabigerol
por: Brierley, Daniel I., et al.
Publicado: (2019)

Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota
por: Luz-Veiga, Mariana, et al.
Publicado: (2023)

Mannich-type modifications of (−)-cannabidiol and (−)-cannabigerol leading to new, bioactive derivatives
por: Lőrincz, Eszter Boglárka, et al.
Publicado: (2023)

Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats
por: Brierley, Daniel I, et al.
Publicado: (2016)

Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma
por: Lah, Tamara T., et al.
Publicado: (2021)

Cannabidiol and Cannabigerol Modify the Composition and Physicochemical Properties of Keratinocyte Membranes Exposed to UVA
por: Wroński, Adam, et al.
Publicado: (2023)

Metabolic Origins and Transport of Vitamin E Biosynthetic Precursors
por: Pellaud, Sébastien, et al.
Publicado: (2017)

Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease
por: Benson, Melissa J, et al.
Publicado: (2020)

Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ(9)-THC at Human CB(1) and CB(2) Receptors
por: Santiago, Marina, et al.
Publicado: (2019)

Profiling Cannabinoid Contents and Expression Levels of Corresponding Biosynthetic Genes in Commercial Cannabis (Cannabis sativa L.) Cultivars
por: Kim, Ae Lim, et al.
Publicado: (2022)

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
por: Stone, Nicole L., et al.
Publicado: (2021)

Cannabigerol Effect on Streptococcus mutans Biofilms—A Computational Approach to Confocal Image Analysis
por: Aqawi, Muna, et al.
Publicado: (2022)

Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways
por: Viereckl, Michael J., et al.
Publicado: (2022)

Non-psychotropic phytocannabinoid interactions with voltage-gated sodium channels: An update on cannabidiol and cannabigerol
por: Ghovanloo, Mohammad-Reza, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vuug4ot12l3nppcim8l66rs57l